The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of denosumab versus zoledronic acid in patients with castrate-resistant prostate cancer and bone metastases: Subgroup analyses by prior SRE and baseline pain.
N. D. Shore
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
M. R. Smith
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
M. Jievaltas
No relevant relationships to disclose
K. Fizazi
Consultant or Advisory Role - Amgen
Honoraria - Amgen
R. DamiĆ£o
No relevant relationships to disclose
J. Chin
Consultant or Advisory Role - Amgen
Research Funding - Amgen
K. Miller
Consultant or Advisory Role - Amgen
Honoraria - Amgen
J. P. Maroto
No relevant relationships to disclose
Y. Qian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
A. Feng
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Chung
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. D. Goessl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen